159 related articles for article (PubMed ID: 3124166)
1. The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate.
Midha KK; Hubbard JW; Marder SR; Hawes EM; Van Putten T; McKay G; May PR
Psychopharmacology (Berl); 1987; 93(3):369-73. PubMed ID: 3124166
[TBL] [Abstract][Full Text] [Related]
2. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
Chang SS; Javaid JI; Dysken MW; Casper RC; Janicak PG; Davis JM
Psychopharmacology (Berl); 1985; 87(1):55-8. PubMed ID: 3933037
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Midha KK
Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassay.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Hubbard JW; Midha KK
Ther Drug Monit; 1990 May; 12(3):268-76. PubMed ID: 2349611
[TBL] [Abstract][Full Text] [Related]
6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
7. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
8. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
11. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
12. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
13. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Norman TR; Marriott PF; Kimber NM; Burrows GD
Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
[TBL] [Abstract][Full Text] [Related]
14. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
[TBL] [Abstract][Full Text] [Related]
15. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Glazer WM; Friedhoff LT; Marder SR; Brown WA
Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
[TBL] [Abstract][Full Text] [Related]
16. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
17. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
[No Abstract] [Full Text] [Related]
18. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]